179 related articles for article (PubMed ID: 38061356)
1. Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers.
Stokes ME; Vasciaveo A; Small JC; Zask A; Reznik E; Smith N; Wang Q; Daniels J; Forouhar F; Rajbhandari P; Califano A; Stockwell BR
Cell Chem Biol; 2024 Apr; 31(4):805-819.e9. PubMed ID: 38061356
[TBL] [Abstract][Full Text] [Related]
2. Kinases Controlling Stability of the Oncogenic MYCN Protein.
Smith N; Reznik E; Bisikirska B; Polychronidou V; Wang Q; Zask A; Forouhar F; Califano A; Stockwell BR
ACS Med Chem Lett; 2023 Dec; 14(12):1664-1672. PubMed ID: 38116412
[TBL] [Abstract][Full Text] [Related]
3. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal subtype neuroblastomas are addicted to TGF-βR2/HMGCR-driven protein geranylgeranylation.
Stokes ME; Small JC; Vasciaveo A; Shimada K; Hirschhorn T; Califano A; Stockwell BR
Sci Rep; 2020 Jul; 10(1):10748. PubMed ID: 32612149
[TBL] [Abstract][Full Text] [Related]
5. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
6. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
7. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
8. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
[TBL] [Abstract][Full Text] [Related]
9. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
[TBL] [Abstract][Full Text] [Related]
10. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
12. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
13. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
14. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
15. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.
Duffy DJ; Krstic A; Halasz M; Schwarzl T; Fey D; Iljin K; Mehta JP; Killick K; Whilde J; Turriziani B; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
Oncotarget; 2015 Dec; 6(41):43182-201. PubMed ID: 26673823
[TBL] [Abstract][Full Text] [Related]
16. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
17. MYCN induces neuroblastoma in primary neural crest cells.
Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
[TBL] [Abstract][Full Text] [Related]
18. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
20. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]